

Date: 13<sup>th</sup> August, 2025

To,

**BSE Limited**

Department of Corporate Services

P. J. Towers,

Dalal Street, Fort,

Mumbai – 400001.

**Scrip Code: 511523**

Sub: **Press Release on the Unaudited Financial Results for the Quarter Ended June 30, 2025**

Dear Sir/ Madam,

We are enclosing herewith the Press Release dated 13<sup>th</sup> August, 2025 on the Unaudited Financial Results for the quarter ended June 30, 2025.

We request you to kindly take the same on record.

Thanking You.

Yours truly,

For **Veerhealth Care Limited**



Bhavin S. Shah  
Managing Director  
DIN: 03129574



## **Veerhealth Care Limited Reports Robust 112.40% Year-over- Year growth at ₹ 5.14 Crore in Total Income in Q1 FY26**

**Mumbai – 13<sup>th</sup> August, 2025:** Veerhealth Care Limited (BSE: VEERHEALTH), Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.

### **Q1 FY26 Standalone Financial Highlights**

- Total Income of ₹ 5.14 Crore, YoY growth of 112.40%
- EBITDA of ₹ 0.62 Crore, YoY growth of 82.35%
- EBITDA Margin of 12.06%
- Net Profit of ₹ 0.24 Crore, YoY growth of 104.08%
- Net Profit Margin of 4.67%

Note- Results for Q1 FY26 are not comparable with Q4 FY25 because for successfully clearing the USFDA Inspection the Company had to expand, renovate and upgrade the Manufacturing facility due to which Production was impacted in the past 6-9 months, also Exports were halted for USFDA clearance.

### **Key Highlights**

- Veerhealth Care has received USFDA clearance, enabling exports of Drug (OTC) products to the USA and unlocking access to other international markets, in line with its “**Local to Global**” vision. It is one of the leading small-cap companies in India in the Food & Drug (OTC) segment with a USFDA-approved plant. Despite its size, the Company is now in the league of larger players, eligible for larger export orders. Very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.
- In line with its “**Local to Global**” ambition, Veerhealth Care is actively working towards scaling its manufacturing and export operations for products under the medical device category in the U.S. market. The Company has successfully completed the formalities with the USFDA under this category, marking a strategic move to diversify and strengthen its international footprint in the healthcare segment.
- Received regulatory approval from Food and Drug Authority, Gujarat for manufacturing personal care products for a leading marketplace company.
- Signed agreement to produce private-label personal care products; commercial production to begin post regulatory approval.
- Secured first commercial order worth ₹0.48 crore for skin care and face care product manufacturing.
- Dispatched 3 FCL Export shipments to the US; 4–5 monthly shipments targeted.
- Received ₹0.74 crore export order for oral care products; to be fulfilled in 30 days.
- Discussions ongoing with a major Russian group for oral care exports; expected entry into Russian market soon.
- Completed onboarding of Ayuveer products on Myntra, expanding e-commerce presence. Now present across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.
- Commenced production at new facility with in-house plastic molding for packaging and backward integration.

**Commenting on the financial performance, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said,** “I am delighted with the strides we have made in Q1 FY26, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets.

Our ability to secure multiple high-value export orders, including those from top institutional suppliers, underscores the trust in our product quality and commitment to excellence. The expansion of our manufacturing footprint further reflects our proactive approach to meeting growing demand and enhancing our production capabilities. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters."

**Very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.**

**Veerhealth Care Limited specializes in manufacturing of Pure Vegetarian toothpaste.**

**In F.Y. 2025-26 we are expecting Total Revenues of ₹ 30-35 crores with PAT of 10%.**

**Veerhealth Care is expecting to reach Revenue of ₹ 100 crores with PAT of 10% in next 24 to 36 months.**

#### **Disclaimer**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.